RhumbLine Advisers’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-107,645
| Closed | -$1.21M | – | 2892 |
|
|
2017
Q3 | $1.21M | Buy |
107,645
+1,610
| +2% | +$17.8K | ﹤0.01% | 1882 |
|
|
2017
Q2 | $1.17M | Buy |
106,035
+4,863
| +5% | +$48.6K | ﹤0.01% | 1865 |
|
|
2017
Q1 | $991K | Buy |
101,172
+30,804
| +44% | +$308K | ﹤0.01% | 1916 |
|
|
2016
Q4 | $760K | Buy |
70,368
+4,930
| +8% | +$49.3K | ﹤0.01% | 2000 |
|
|
2016
Q3 | $671K | Buy |
65,438
+2,930
| +5% | +$31.9K | ﹤0.01% | 2038 |
|
|
2016
Q2 | $816K | Buy |
62,508
+10,965
| +21% | +$144K | ﹤0.01% | 1910 |
|
|
2016
Q1 | $567K | Buy |
51,543
+80
| +0.2% | +$711 | ﹤0.01% | 2137 |
|
|
2015
Q4 | $473K | Buy |
51,463
+4,235
| +9% | +$35.4K | ﹤0.01% | 2269 |
|
|
2015
Q3 | $328K | Buy |
47,228
+2,136
| +5% | +$18.3K | ﹤0.01% | 2481 |
|
|
2015
Q2 | $443K | Sell |
45,092
-16,715
| -27% | -$152K | ﹤0.01% | 2413 |
|
|
2015
Q1 | $548K | Buy |
61,807
+7,400
| +14% | +$58.9K | ﹤0.01% | 2250 |
|
|
2014
Q4 | $477K | Buy |
54,407
+2,545
| +5% | +$20.6K | ﹤0.01% | 2306 |
|
|
2014
Q3 | $357K | Sell |
51,862
-350
| -0.7% | -$2.1K | ﹤0.01% | 2420 |
|
|
2014
Q2 | $275K | Sell |
52,212
-20
| -0% | -$97 | ﹤0.01% | 2653 |
|
|
2014
Q1 | $238K | Sell |
52,232
-2,630
| -5% | -$12.7K | ﹤0.01% | 2674 |
|
|
2013
Q4 | $277K | Sell |
54,862
-1,300
| -2% | -$6.26K | ﹤0.01% | 2638 |
|
|
2013
Q3 | $285K | Sell |
56,162
-491
| -0.9% | -$2.73K | ﹤0.01% | 2563 |
|
|
2013
Q2 | $281K | Buy |
+56,653
| New | +$270K | ﹤0.01% | 2702 |
|
RhumbLine Advisers's SCLN Position: Q4 2017 in Review
RhumbLine Advisers sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 107,645 shares — an estimated $1.21M sold.
RhumbLine Advisers first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $1.21M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- RhumbLine Advisers reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- RhumbLine Advisers sold 107,645 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.21M.
- RhumbLine Advisers first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- RhumbLine Advisers's Sciclone Pharmaceuticals Inc position peaked at $1.21M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on RhumbLine Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.